Stockscreener 앱 받기
11.60
5.94%
0.65
시간 외 거래:
11.60
전일 마감가:
$10.95
열려 있는:
$10.87
하루 거래량:
820.62K
Relative Volume:
1.58
시가총액:
$675.44M
수익:
-
순이익/손실:
$-153.16M
주가수익비율:
-3.4421
EPS:
-3.37
순현금흐름:
$-134.48M
1주 성능:
-1.28%
1개월 성능:
-7.79%
6개월 성능:
-33.75%
1년 성능:
+32.72%
1일 변동 폭
$10.78
$11.86
1주일 범위
$10.44
$12.06
52주 변동 폭
$8.49
$30.19
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
CGEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
11.60 | 675.44M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
State Street Corp Buys 396,034 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat
Cullinan Therapeutics' chief medical officer sells $52,851 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics chief scientific officer sells $53,547 in stock - Investing.com
Cullinan Therapeutics' chief medical officer sells $52,851 in stock - Investing.com India
Cullinan therapeutics chief legal officer sells $39,729 in stock - Investing.com India
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6%What's Next? - MarketBeat
Fmr LLC Purchases 19,681 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Franklin Resources Inc. Sells 252,868 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 4%Here's Why - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.19 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 3,489 Shares of Stock - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Charles Schwab Investment Management Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Purchased by RTW Investments LP - MarketBeat
Patient Square Capital LP Acquires New Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Holocene Advisors LP - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Walleye Capital LLC - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Braidwell LP - MarketBeat
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $31.67 - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $31.67 Average Target Price from Brokerages - MarketBeat
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks
What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat
Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com
CGEMCullinan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Biotechnology Value Fund L.P. Expands Stake in Cullinan Therapeu - GuruFocus.com
Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada
Cullinan advances lupus treatment with new clinical trial - Investing.com
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India
Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com
Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times
Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics Advances Pipeline Despite $40.6M Loss; Maintains $639M Cash Position | CGEM Stock News - StockTitan
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan
Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat
FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat
Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):